Testing one peptide vial provides evidence about the submitted sample and measured attributes. A wider batch conclusion also needs a documented sampling plan; repeated readings of that vial do not directly measure other vials.
Ask what was repeated
| Activity | What it repeats | What remains unobserved |
|---|---|---|
| Repeated injections from one sample | Instrument measurement | Between-vial variation |
| Repeated laboratory subsamples from one vial | Subsampling and measurement of that vial | Other filled vials |
| Separately selected vials | Different physical units | Unsampled units and selection limitations |
The supplied Semax report mentions duplicate independent preparations, but does not identify the number of separately selected vials or the selection plan. Preserve that limit when describing its lot coverage.Semax report (PDF) (opens in a new tab)
An average can conceal differences
Consider two illustrative sets of vial amounts: 8, 10 and 12 mg; and 10, 10 and 10 mg. Both average 10 mg, but have different spreads. A pooled result or a mean alone cannot recover the individual values. These invented figures are not product results or recommended limits.NIST sampling principles (opens in a new tab)
A result from a portion of a vial also depends on whether that portion represents the relevant material. Keep whole-vial content, sampled-portion concentration and pooled material as different descriptions.NIST sampling plans (opens in a new tab)
Read the selection plan
For a lot held in ten cartons, selecting only the most accessible carton is different from a plan that represents the whole defined lot. Useful records name the lot size, selected units, selection method and whether units were analysed separately or combined. NIST frames a sampling plan around what, when, where and how to measure.NIST sampling plans (opens in a new tab)NIST sampling principles (opens in a new tab)
Blind sample coding and external-laboratory testing address different questions. Coding concerns what the analyst can identify from the label; organisational independence concerns who performs the work. Neither supplies a missing lot-selection plan.Parsons et al. (2001), PMID 11159782 (opens in a new tab)NIST sampling plans (opens in a new tab)
A concise conclusion can state the number of independently selected vials, the tests and the remaining sampling gap. One passing vial is not a measured census of the lot, and this guide assigns no universal sample count.NIST sampling principles (opens in a new tab)NIST sampling plans (opens in a new tab)
Sources and further detail
- Supplied Semax 10 mg certificate (opens in a new tab)
MA-SEM-0041, revision 01; task DMAS3J7; lot SEM-41-3J7. Document-specific facts are transcriptions, not authentication. The cited PDF was re-read on 3 October 2026 to check this transcription; its issuer and findings were not independently authenticated.
- NIST/SEMATECH — Populations and sampling (opens in a new tab)
Statistical background on sample-to-population inference; the vial scenarios are original illustrations.
- NIST/SEMATECH — Defining a sampling plan (opens in a new tab)
Background on specifying a sampling plan. Not a product-specific sampling recommendation.
- Parsons et al. (2001), PMID 11159782 (opens in a new tab)
Used only for the distinction between open and blind analytical comparison; study-specific findings are not transferred to peptide testing.
Revised from the existing source dossier on 3 October 2026. Supplied-report values are document transcriptions, not independent authentication or new measurements. Source notes identify the scope of each reference; this article has not undergone independent scientific peer review.